Le Lézard
Classified in: Health, Science and technology, Business
Subject: PDT

Halespring Launches Equity Crowdfunding Campaign for HIPAA-Compliant Platform to Empower Mental Health Providers


Halespring, a pioneering mental health technology startup, is excited to announce the opening of its crowdfunding campaign on WeFunder, the leading SEC regulated equity crowdfunding site.

WESTPORT, Conn., May 17, 2024 /PRNewswire-PRWeb/ -- Halespring, a pioneering mental health technology startup, is excited to announce the opening of its crowdfunding campaign on WeFunder, the leading SEC regulated equity crowdfunding site. Halespring is dedicated to transforming the mental healthcare system with a robust, HIPAA compliant platform providing essential features for mental health professionals, patients, and their loved ones.

The Halespring platform is tailor-made to help mental health professionals with things like knowledge sharing, collaboration, and streamlined referrals.

The mental health treatment ecosystem faces significant challenges despite the best efforts of therapists, counselors, psychiatrists, and other mental health providers. These dedicated professionals team up everyday to help their patients, but they struggle to communicate or collaborate with each other because they don't have a HIPAA-compliant tool to do so. This gap leads to inefficiencies for providers and compromised or delayed care for patients, especially those with complex or more urgent needs.

"The Halespring journey began after many years spent helping an adolescent family member navigate the challenges of mental health care. Our mission is to create an effective product and a strong business. By mending what is broken in our mental healthcare system, we believe we are filling a void," said Michael Hermus, CEO of Halespring. "The Halespring platform is tailor-made to help mental health professionals with things like knowledge sharing, collaboration, and streamlined referrals. I am incredibly excited to see the positive impact Halespring can bring to the millions of patients seeking mental health treatment by empowering their dedicated providers."

According to a market survey, 97 percent of mental health providers indicated interest in using a product like Halespring. This strong market validation underscores the gap in current tools available today, and highlights the need for a specialized solution. Upon its 2024 launch, Halespring will be uniquely positioned as the only fully-built, HIPAA-compliant software platform, specifically focused on the needs of mental health professionals.

"By participating in our WeFunder campaign with as little as $100, people have the unique opportunity to invest in a promising technology startup, while also becoming a part of something that really matters: helping to address our ongoing national mental health crisis," continued Hermus.

Early investors in the first $250K will enter a SAFE with a $4.4M valuation cap. Learn more here: https://wefunder.com/halespring

Halespring was selected to present at the 2024 Yale Innovation Summit on May 29 ? 30 in New Haven, CT.

About Halespring

Halespring is developing cutting-edge technology solutions that address the critical needs of the mental healthcare community. By providing tools to enhance collaboration and efficiency, Halespring helps healthcare professionals deliver superior care to their patients. Learn more by visiting: https://halespring.com.

Media Contact

Michael Hermus, Halespring, 1 9173706016, [email protected], https://halespring.com/pages/home

SOURCE Halespring


These press releases may also interest you

at 09:05
Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced today that it is presenting a Trial in Progress poster for the phase 1 ANCHOR clinical...

at 09:00
The American Cancer Society (ACS) and the American Society of Clinical Oncology (ASCO) today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the...

at 09:00
Beverly Hills MD®, the cutting-edge skincare line created by renowned plastic surgeons Dr. John Layke and Dr. Payman Danielpour, is celebrating its 10th anniversary. Founded in 2014 by Dr. Layke and Dr. Danielpour, who co-founded the Beverly Hills...

at 08:30
Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device...

at 08:15
Nuvation Bio Inc. , a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, its...

at 08:05
Takeda (TSE:4502/NYSE:TAK) and Pfizer today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking...



News published on and distributed by: